307 related articles for article (PubMed ID: 18691111)
1. Antifungal agents in hematopoietic stem cell transplantation.
Parameswaran GI; Segal BH; Almyroudis NG
Curr Pharm Des; 2008; 14(20):2011-21. PubMed ID: 18691111
[TBL] [Abstract][Full Text] [Related]
2. Role of new antifungal agents in prophylaxis of mycoses in high risk patients.
van Burik JA
Curr Opin Infect Dis; 2005 Dec; 18(6):479-83. PubMed ID: 16258319
[TBL] [Abstract][Full Text] [Related]
3. Antifungal prophylaxis in adult hematopoietic stem cell transplant recipients.
Tamura K; Drew R
Drugs Today (Barc); 2008 Jul; 44(7):515-30. PubMed ID: 18806902
[TBL] [Abstract][Full Text] [Related]
4. Complications of hematopoietic stem transplantation: Fungal infections.
Omrani AS; Almaghrabi RS
Hematol Oncol Stem Cell Ther; 2017 Dec; 10(4):239-244. PubMed ID: 28636889
[TBL] [Abstract][Full Text] [Related]
5. Antifungal prophylaxis among allogeneic hematopoietic stem cell transplant recipients: current issues and new agents.
Strasfeld L; Weinstock DM
Expert Rev Anti Infect Ther; 2006 Jun; 4(3):457-68. PubMed ID: 16771622
[TBL] [Abstract][Full Text] [Related]
6. Broad-spectrum antifungal prophylaxis in patients with cancer at high risk for invasive mold infections: point.
Gonzalez AV; Ullmann AJ; Almyroudis NG; Segal BH
J Natl Compr Canc Netw; 2008 Feb; 6(2):175-82. PubMed ID: 18319049
[TBL] [Abstract][Full Text] [Related]
7. Primary antifungal prophylaxis in adult hematopoietic stem cell transplant recipients: current therapeutic concepts.
McCoy D; Depestel DD; Carver PL
Pharmacotherapy; 2009 Nov; 29(11):1306-25. PubMed ID: 19857148
[TBL] [Abstract][Full Text] [Related]
8. Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China: a multicenter prospective observational study.
Sun Y; Meng F; Han M; Zhang X; Yu L; Huang H; Wu D; Ren H; Wang C; Shen Z; Ji Y; Huang X
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1117-26. PubMed ID: 25840339
[TBL] [Abstract][Full Text] [Related]
9. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.
Ullmann AJ; Lipton JH; Vesole DH; Chandrasekar P; Langston A; Tarantolo SR; Greinix H; Morais de Azevedo W; Reddy V; Boparai N; Pedicone L; Patino H; Durrant S
N Engl J Med; 2007 Jan; 356(4):335-47. PubMed ID: 17251530
[TBL] [Abstract][Full Text] [Related]
10. Systemic antifungal prophylaxis after hematopoietic stem cell transplantation: a meta-analysis.
Ziakas PD; Kourbeti IS; Mylonakis E
Clin Ther; 2014 Feb; 36(2):292-306.e1. PubMed ID: 24439393
[TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole versus fluconazole in allogeneic blood hematopoietic stem cell transplantation recipients-A retrospective analysis of a single medical center in Taiwan.
Wang CH; Kan LP; Lin HA; Chang FY; Wang NC; Lin TY; Chao TY; Kao WY; Ho CL; Chen YC; Dai MS; Chang PY; Wu YY; Lin JC
J Microbiol Immunol Infect; 2016 Aug; 49(4):531-8. PubMed ID: 25440977
[TBL] [Abstract][Full Text] [Related]
12. [Is micafungin useful in the prophylaxis of invasive fungal disease in hematological patients?].
Salavert M; Jarque I
Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():43-9. PubMed ID: 21420577
[TBL] [Abstract][Full Text] [Related]
13. Fungal infections in patients undergoing blood and marrow transplantation.
Marr KA; Bowden RA
Transpl Infect Dis; 1999 Dec; 1(4):237-46. PubMed ID: 11428995
[TBL] [Abstract][Full Text] [Related]
14. Voriconazole is safe and effective as prophylaxis for early and late fungal infections following allogeneic hematopoietic stem cell transplantation.
Martin T; Sharma M; Damon L; Kaplan L; Guglielmo BJ; Working M; O'Malley R; Hwang J; Linker C
Transpl Infect Dis; 2010 Feb; 12(1):45-50. PubMed ID: 19793068
[TBL] [Abstract][Full Text] [Related]
15. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial.
Winston DJ; Maziarz RT; Chandrasekar PH; Lazarus HM; Goldman M; Blumer JL; Leitz GJ; Territo MC
Ann Intern Med; 2003 May; 138(9):705-13. PubMed ID: 12729424
[TBL] [Abstract][Full Text] [Related]
16. Design issues in a prospective randomized double-blinded trial of prophylaxis with fluconazole versus voriconazole after allogeneic hematopoietic cell transplantation.
Wingard JR
Clin Infect Dis; 2004 Oct; 39 Suppl 4():S176-80. PubMed ID: 15546114
[TBL] [Abstract][Full Text] [Related]
17. Antifungal prophylaxis for invasive mycoses in high risk patients.
Ullmann AJ; Cornely OA
Curr Opin Infect Dis; 2006 Dec; 19(6):571-6. PubMed ID: 17075333
[TBL] [Abstract][Full Text] [Related]
18. Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients.
Bow EJ; Vanness DJ; Slavin M; Cordonnier C; Cornely OA; Marks DI; Pagliuca A; Solano C; Cragin L; Shaul AJ; Sorensen S; Chambers R; Kantecki M; Weinstein D; Schlamm H
BMC Infect Dis; 2015 Mar; 15():128. PubMed ID: 25887385
[TBL] [Abstract][Full Text] [Related]
19. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts.
Segal BH; Almyroudis NG; Battiwalla M; Herbrecht R; Perfect JR; Walsh TJ; Wingard JR
Clin Infect Dis; 2007 Feb; 44(3):402-9. PubMed ID: 17205448
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for recurrence of invasive fungal infection during secondary antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients.
Liu F; Wu T; Wang JB; Cao XY; Yin YM; Zhao YL; Lu DP
Transpl Infect Dis; 2013 Jun; 15(3):243-50. PubMed ID: 23496156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]